title: [Curative antifungal treatment of invasive pulmonary aspergillosis].
abstract: Pulmonary invasive aspergillosis is a frequent and poor prognosis complication of immunodeficiency and prolonged neutropenia. Its treatment is usually based on amphotericin given as intravenous infusion at 1 to 1.25 mg/kg/d. Use of lipid carriers give the opportunity to administrated higher dose, 5 mg/kg/d, with respect of renal function and good results in the primarily study. Intraconazole is now a good therapy after amphotericin, in the second time of disease.
authors.affiliation: Service de pneumologie, CHU de Strasbourg.
authors.forename: E
authors.initials: E
authors.lastname: Andrès
authors.forename: F
authors.initials: F
authors.lastname: Courouau
authors.forename: J E
authors.initials: JE
authors.lastname: Kurtz
authors.forename: J M
authors.initials: JM
authors.lastname: Limacher
authors.forename: E
authors.initials: E
authors.lastname: Quoix
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B